Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer-Reference-Cited by-同舟云学术

Multiagent Chemotherapy Followed by Stereotactic Body Radiotherapy Versus Conventional Radiotherapy for Resected Pancreas Cancer

Published:2022-10-21 Issue:11 Volume:45 Page:450-457
ISSN:0277-3732
Container-title:American Journal of Clinical Oncology
language:en
Short-container-title:

Author:

Mokhtech Meriem,Miccio Joseph A.,Johung Kimberly,Cecchini Michael,Stein Stacey,Narang Amol K.,Herman Joseph M.,Kunstman John,Haddock Michael G.,Anker Christopher J.,Jabbour Salma,Hallemeier Christopher L.,Jethwa Krishan R.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Oncology

Reference46 articles.

1. Pancreatic adenocarcinoma;Ryan;N Engl J Med,2014

2. Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial;Doi;Surg Today,2008

3. A margin-negative R0 resection accomplished with minimal postoperative complications is the surgeon’s contribution to long-term survival in pancreatic cancer;Howard;J Gastrointest Surg,2006

4. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer;Conroy;N Engl J Med,2018

5. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial;Neoptolemos;Lancet,2017

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer;Clinical and Experimental Gastroenterology;2024-07

2. Executive Summary of the American Radium Society Appropriate Use Criteria for Neoadjuvant Therapy for Nonmetastatic Pancreatic Adenocarcinoma;American Journal of Clinical Oncology;2023-12-22